{"entity":{"type":"insider","cik":"0001856369","url":"/insider/0001856369","json_url":"/insider/0001856369.json","name":"Gibson Christopher","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":227,"n_filings":76,"first":"2021-12-09","last":"2026-06-05","span_basis":"filed_date"},"name_variants":[{"name":"Gibson Christopher","source":"filing","n_filings":76,"first_seen":"2021-12-09","last_seen":"2026-06-05"}],"transactions":[{"id":5759437,"accession":"0001856369-26-000023","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-26-000023","line_url":"/filing/0001856369-26-000023#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.62,"price_display":"3.62","price_state":"stated","total_value":144800.0,"total_display":"144,800.00","total_whole":"144,800","shares_owned_after":883735.0,"shares_owned_after_display":"883,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-05","filed_date":"2026-06-05","scope":"insider"},{"id":6205988,"accession":"0001856369-26-000019","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-26-000019","line_url":"/filing/0001856369-26-000019#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.08,"price_display":"3.08","price_state":"stated","total_value":123200.0,"total_display":"123,200.00","total_whole":"123,200","shares_owned_after":883735.0,"shares_owned_after_display":"883,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-27","scope":"insider"},{"id":6142117,"accession":"0001856369-26-000015","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-26-000015","line_url":"/filing/0001856369-26-000015#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.37,"price_display":"3.37","price_state":"stated","total_value":134800.0,"total_display":"134,800.00","total_whole":"134,800","shares_owned_after":926556.0,"shares_owned_after_display":"926,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-07","filed_date":"2026-05-08","scope":"insider"},{"id":5900348,"accession":"0001856369-26-000013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-26-000013","line_url":"/filing/0001856369-26-000013#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.61,"price_display":"3.61","price_state":"stated","total_value":144400.0,"total_display":"144,400.00","total_whole":"144,400","shares_owned_after":906556.0,"shares_owned_after_display":"906,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-22","filed_date":"2026-04-24","scope":"insider"},{"id":5779588,"accession":"0001856369-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-26-000008","line_url":"/filing/0001856369-26-000008#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.1,"price_display":"3.10","price_state":"stated","total_value":124000.0,"total_display":"124,000.00","total_whole":"124,000","shares_owned_after":906556.0,"shares_owned_after_display":"906,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-07","filed_date":"2026-04-08","scope":"insider"},{"id":6131328,"accession":"0001601830-26-000052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-26-000052","line_url":"/filing/0001601830-26-000052#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.25,"price_display":"3.25","price_state":"stated","total_value":130000.0,"total_display":"130,000.00","total_whole":"130,000","shares_owned_after":906556.0,"shares_owned_after_display":"906,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-23","filed_date":"2026-03-25","scope":"insider"},{"id":5882161,"accession":"0001601830-26-000021","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001601830-26-000021","line_url":"/filing/0001601830-26-000021#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":3.46,"price_display":"3.46","price_state":"stated","total_value":138400.0,"total_display":"138,400.00","total_whole":"138,400","shares_owned_after":906556.0,"shares_owned_after_display":"906,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-19","filed_date":"2026-02-19","scope":"insider"},{"id":6039591,"accession":"0001601830-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-26-000008","line_url":"/filing/0001601830-26-000008#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.12,"price_display":"4.12","price_state":"stated","total_value":164800.0,"total_display":"164,800.00","total_whole":"164,800","shares_owned_after":913839.0,"shares_owned_after_display":"913,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-06","scope":"insider"},{"id":5938244,"accession":"0001856369-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-26-000005","line_url":"/filing/0001856369-26-000005#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.47,"price_display":"4.47","price_state":"stated","total_value":178800.0,"total_display":"178,800.00","total_whole":"178,800","shares_owned_after":913839.0,"shares_owned_after_display":"913,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-20","filed_date":"2026-01-22","scope":"insider"},{"id":5877022,"accession":"0001856369-26-000003","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-26-000003","line_url":"/filing/0001856369-26-000003#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.25,"price_display":"4.25","price_state":"stated","total_value":170000.0,"total_display":"170,000.00","total_whole":"170,000","shares_owned_after":933839.0,"shares_owned_after_display":"933,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4686444,"accession":"0001856369-25-000018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-25-000018","line_url":"/filing/0001856369-25-000018#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.5,"price_display":"4.50","price_state":"stated","total_value":180000.0,"total_display":"180,000.00","total_whole":"180,000","shares_owned_after":913839.0,"shares_owned_after_display":"913,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-19","filed_date":"2025-12-19","scope":"insider"},{"id":4214877,"accession":"0001856369-25-000016","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-25-000016","line_url":"/filing/0001856369-25-000016#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.63,"price_display":"4.63","price_state":"stated","total_value":185200.0,"total_display":"185,200.00","total_whole":"185,200","shares_owned_after":933839.0,"shares_owned_after_display":"933,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-04","filed_date":"2025-12-05","scope":"insider"},{"id":4156010,"accession":"0001856369-25-000014","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-25-000014","line_url":"/filing/0001856369-25-000014#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.16,"price_display":"4.16","price_state":"stated","total_value":166400.0,"total_display":"166,400.00","total_whole":"166,400","shares_owned_after":913839.0,"shares_owned_after_display":"913,839","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-19","filed_date":"2025-11-19","scope":"insider"},{"id":4156004,"accession":"0001856369-25-000012","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-25-000012","line_url":"/filing/0001856369-25-000012#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":5.21,"price_display":"5.21","price_state":"stated","total_value":208400.0,"total_display":"208,400.00","total_whole":"208,400","shares_owned_after":974229.0,"shares_owned_after_display":"974,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-04","filed_date":"2025-11-06","scope":"insider"},{"id":5100658,"accession":"0001856369-25-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-25-000010","line_url":"/filing/0001856369-25-000010#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":5.7,"price_display":"5.70","price_state":"stated","total_value":570000.0,"total_display":"570,000.00","total_whole":"570,000","shares_owned_after":954229.0,"shares_owned_after_display":"954,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-23","filed_date":"2025-10-24","scope":"insider"},{"id":4562049,"accession":"0001856369-25-000007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001856369-25-000007","line_url":"/filing/0001856369-25-000007#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":6.04,"price_display":"6.04","price_state":"stated","total_value":604000.0,"total_display":"604,000.00","total_whole":"604,000","shares_owned_after":974229.0,"shares_owned_after_display":"974,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-10","filed_date":"2025-10-10","scope":"insider"},{"id":4323563,"accession":"0001856369-25-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001856369-25-000005","line_url":"/filing/0001856369-25-000005#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":4.76,"price_display":"4.76","price_state":"stated","total_value":476000.0,"total_display":"476,000.00","total_whole":"476,000","shares_owned_after":954229.0,"shares_owned_after_display":"954,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-25","filed_date":"2025-09-26","scope":"insider"},{"id":4867207,"accession":"0001601830-25-000145","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001601830-25-000145","line_url":"/filing/0001601830-25-000145#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":4.71,"price_display":"4.71","price_state":"stated","total_value":471000.0,"total_display":"471,000.00","total_whole":"471,000","shares_owned_after":974229.0,"shares_owned_after_display":"974,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-10","filed_date":"2025-09-12","scope":"insider"},{"id":4333890,"accession":"0001601830-25-000136","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-25-000136","line_url":"/filing/0001601830-25-000136#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":4.84,"price_display":"4.84","price_state":"stated","total_value":484000.0,"total_display":"484,000.00","total_whole":"484,000","shares_owned_after":954229.0,"shares_owned_after_display":"954,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-26","filed_date":"2025-08-28","scope":"insider"},{"id":4867197,"accession":"0001601830-25-000130","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001601830-25-000130","line_url":"/filing/0001601830-25-000130","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":618175.0,"shares_display":"618,175","price_per_share":5.28,"price_display":"5.28","price_state":"stated","total_value":3263964.0,"total_display":"3,263,964.00","total_whole":"3,263,964","shares_owned_after":1004619.0,"shares_owned_after_display":"1,004,619","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-11","filed_date":"2025-08-13","scope":"insider","n_lines":3},{"id":4534914,"accession":"0001601830-25-000051","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001601830-25-000051","line_url":"/filing/0001601830-25-000051#line-1","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":138574.0,"shares_display":"138,574","price_per_share":6.04,"price_display":"6.04","price_state":"stated","total_value":836986.96,"total_display":"836,986.96","total_whole":"836,987","shares_owned_after":1117450.0,"shares_owned_after_display":"1,117,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-27","filed_date":"2025-03-28","scope":"insider"},{"id":4238038,"accession":"0001601830-25-000037","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-25-000037","line_url":"/filing/0001601830-25-000037#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.37,"price_display":"6.37","price_state":"stated","total_value":127400.0,"total_display":"127,400.00","total_whole":"127,400","shares_owned_after":1256024.0,"shares_owned_after_display":"1,256,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-06","filed_date":"2025-03-07","scope":"insider"},{"id":4238031,"accession":"0001601830-25-000037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-25-000037","line_url":"/filing/0001601830-25-000037#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.58,"price_display":"6.58","price_state":"stated","total_value":131600.0,"total_display":"131,600.00","total_whole":"131,600","shares_owned_after":1256024.0,"shares_owned_after_display":"1,256,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider"},{"id":4723634,"accession":"0001601830-25-000014","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-25-000014","line_url":"/filing/0001601830-25-000014#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":8.12,"price_display":"8.12","price_state":"stated","total_value":162400.0,"total_display":"162,400.00","total_whole":"162,400","shares_owned_after":1273156.0,"shares_owned_after_display":"1,273,156","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-06","filed_date":"2025-02-07","scope":"insider"},{"id":4723625,"accession":"0001601830-25-000014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-25-000014","line_url":"/filing/0001601830-25-000014#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.68,"price_display":"7.68","price_state":"stated","total_value":153600.0,"total_display":"153,600.00","total_whole":"153,600","shares_owned_after":1273156.0,"shares_owned_after_display":"1,273,156","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-05","filed_date":"2025-02-07","scope":"insider"},{"id":4046346,"accession":"0001601830-25-000010","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-25-000010","line_url":"/filing/0001601830-25-000010#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.05,"price_display":"7.05","price_state":"stated","total_value":141000.0,"total_display":"141,000.00","total_whole":"141,000","shares_owned_after":736633.0,"shares_owned_after_display":"736,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-10","filed_date":"2025-01-13","scope":"insider"},{"id":4046344,"accession":"0001601830-25-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-25-000010","line_url":"/filing/0001601830-25-000010#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.31,"price_display":"7.31","price_state":"stated","total_value":146200.0,"total_display":"146,200.00","total_whole":"146,200","shares_owned_after":736633.0,"shares_owned_after_display":"736,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-08","filed_date":"2025-01-13","scope":"insider"},{"id":2363374,"accession":"0001601830-24-000234","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000234","line_url":"/filing/0001601830-24-000234#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.12,"price_display":"7.12","price_state":"stated","total_value":142400.0,"total_display":"142,400.00","total_whole":"142,400","shares_owned_after":736633.0,"shares_owned_after_display":"736,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-05","filed_date":"2024-12-06","scope":"insider"},{"id":2359168,"accession":"0001601830-24-000234","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000234","line_url":"/filing/0001601830-24-000234#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.16,"price_display":"7.16","price_state":"stated","total_value":143200.0,"total_display":"143,200.00","total_whole":"143,200","shares_owned_after":736633.0,"shares_owned_after_display":"736,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-04","filed_date":"2024-12-06","scope":"insider"},{"id":2429215,"accession":"0001601830-24-000207","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000207","line_url":"/filing/0001601830-24-000207#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.35,"price_display":"7.35","price_state":"stated","total_value":147000.0,"total_display":"147,000.00","total_whole":"147,000","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-14","filed_date":"2024-11-15","scope":"insider"},{"id":2429207,"accession":"0001601830-24-000207","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000207","line_url":"/filing/0001601830-24-000207#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":7.74,"price_display":"7.74","price_state":"stated","total_value":154800.0,"total_display":"154,800.00","total_whole":"154,800","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-13","filed_date":"2024-11-15","scope":"insider"},{"id":2258988,"accession":"0001601830-24-000172","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000172","line_url":"/filing/0001601830-24-000172#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.08,"price_display":"6.08","price_state":"stated","total_value":121600.0,"total_display":"121,600.00","total_whole":"121,600","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-03","filed_date":"2024-10-04","scope":"insider"},{"id":2258981,"accession":"0001601830-24-000172","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000172","line_url":"/filing/0001601830-24-000172#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.16,"price_display":"6.16","price_state":"stated","total_value":123200.0,"total_display":"123,200.00","total_whole":"123,200","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-02","filed_date":"2024-10-04","scope":"insider"},{"id":2114902,"accession":"0001601830-24-000155","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000155","line_url":"/filing/0001601830-24-000155#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.14,"price_display":"6.14","price_state":"stated","total_value":122800.0,"total_display":"122,800.00","total_whole":"122,800","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-05","filed_date":"2024-09-06","scope":"insider"},{"id":2114894,"accession":"0001601830-24-000155","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000155","line_url":"/filing/0001601830-24-000155#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.04,"price_display":"6.04","price_state":"stated","total_value":120800.0,"total_display":"120,800.00","total_whole":"120,800","shares_owned_after":762656.0,"shares_owned_after_display":"762,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-04","filed_date":"2024-09-06","scope":"insider"},{"id":2290597,"accession":"0001601830-24-000122","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000122","line_url":"/filing/0001601830-24-000122#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":6.5,"price_display":"6.50","price_state":"stated","total_value":130000.0,"total_display":"130,000.00","total_whole":"130,000","shares_owned_after":758738.0,"shares_owned_after_display":"758,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-08","filed_date":"2024-08-09","scope":"insider"},{"id":2290585,"accession":"0001601830-24-000122","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000122","line_url":"/filing/0001601830-24-000122#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":7.1,"price_display":"7.10","price_state":"stated","total_value":213000.0,"total_display":"213,000.00","total_whole":"213,000","shares_owned_after":758738.0,"shares_owned_after_display":"758,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-07","filed_date":"2024-08-09","scope":"insider"},{"id":3186262,"accession":"0001601830-24-000103","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001601830-24-000103","line_url":"/filing/0001601830-24-000103#line-5","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":7.47,"price_display":"7.47","price_state":"stated","total_value":373500.0,"total_display":"373,500.00","total_whole":"373,500","shares_owned_after":758738.0,"shares_owned_after_display":"758,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-11","filed_date":"2024-07-12","scope":"insider"},{"id":3186257,"accession":"0001601830-24-000103","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001601830-24-000103","line_url":"/filing/0001601830-24-000103#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":7.48,"price_display":"7.48","price_state":"stated","total_value":374000.0,"total_display":"374,000.00","total_whole":"374,000","shares_owned_after":758738.0,"shares_owned_after_display":"758,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-10","filed_date":"2024-07-12","scope":"insider"},{"id":2915487,"accession":"0001601830-24-000077","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001601830-24-000077","line_url":"/filing/0001601830-24-000077#line-4","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":450000.0,"total_display":"450,000.00","total_whole":"450,000","shares_owned_after":708738.0,"shares_owned_after_display":"708,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-06","filed_date":"2024-06-07","scope":"insider"},{"id":2915482,"accession":"0001601830-24-000077","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001601830-24-000077","line_url":"/filing/0001601830-24-000077#line-3","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":8.42,"price_display":"8.42","price_state":"stated","total_value":421000.0,"total_display":"421,000.00","total_whole":"421,000","shares_owned_after":758738.0,"shares_owned_after_display":"758,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-05","filed_date":"2024-06-07","scope":"insider"},{"id":2114879,"accession":"0001601830-24-000047","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001601830-24-000047","line_url":"/filing/0001601830-24-000047","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":8.47,"price_display":"8.47","price_state":"stated","total_value":423500.0,"total_display":"423,500.00","total_whole":"423,500","shares_owned_after":834820.0,"shares_owned_after_display":"834,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-02","filed_date":"2024-05-03","scope":"insider","n_lines":2},{"id":2114871,"accession":"0001601830-24-000047","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001601830-24-000047","line_url":"/filing/0001601830-24-000047#line-2","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":7.73,"price_display":"7.73","price_state":"stated","total_value":386500.0,"total_display":"386,500.00","total_whole":"386,500","shares_owned_after":863524.0,"shares_owned_after_display":"863,524","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-01","filed_date":"2024-05-03","scope":"insider"},{"id":2123042,"accession":"0001628280-24-015103","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001628280-24-015103","line_url":"/filing/0001628280-24-015103","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65000.0,"shares_display":"65,000","price_per_share":9.02,"price_display":"9.02","price_state":"stated","total_value":586300.0,"total_display":"586,300.00","total_whole":"586,300","shares_owned_after":938524.0,"shares_owned_after_display":"938,524","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-04","filed_date":"2024-04-05","scope":"insider","n_lines":2},{"id":2123036,"accession":"0001628280-24-015103","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-24-015103","line_url":"/filing/0001628280-24-015103","is_derivative":false,"issuer_cik":"0001601830","issuer_name":"RECURSION PHARMACEUTICALS, INC.","issuer_ticker":"RXRX","issuer_name_source":null,"issuer_url":"/issuer/0001601830","owner_cik":"0001856369","owner_name":"Gibson Christopher","owner_display_name":"Gibson Christopher","owner_url":"/insider/0001856369","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65000.0,"shares_display":"65,000","price_per_share":8.84,"price_display":"8.84","price_state":"stated","total_value":574600.0,"total_display":"574,600.00","total_whole":"574,600","shares_owned_after":978524.0,"shares_owned_after_display":"978,524","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-03","filed_date":"2024-04-05","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2024-04-03|2123034","ledger_fault":false,"count":{"value":227,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":227,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":227},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001601830","name":"RECURSION PHARMACEUTICALS, INC.","url":"/issuer/0001601830","role":"Director, Officer (Chief Executive Officer)","n_filings":76,"first_seen":"2021-12-09","last_seen":"2026-06-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001856369","retrieved_at":"2026-08-25T19:30:47+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}